PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo.
Okuda M, Hijikuro I, Fujita Y, Wu X, Nakayama S, Sakata Y, Noguchi Y, Ogo M, Akasofu S, Ito Y, Soeda Y, Tsuchiya N, Tanaka N, Takahashi T, Sugimoto H.
Okuda M, et al. Among authors: wu x.
PLoS One. 2015 Feb 6;10(2):e0117511. doi: 10.1371/journal.pone.0117511. eCollection 2015.
PLoS One. 2015.
PMID: 25659102
Free PMC article.